Allergy Therapeutics expects full-year revenue in line with expectations

09:54 12/07/2018
StockMarketWire.com - Allergy Therapeutics said Thursday it expected that full-year revenues and expenses would be in-line with market expectations amid 'strong' performance in an 'unusually weak' pollen season.

For the year ended 30 June 2018, reported revenues are expected to come in at £68.3m, up 6.6% from £64.1m the previous year.

The company said it gained a 0.7 market share point within its core markets in Europe.

The cash balance at the end of June 2018 was £15.5m compared with £22.1m the previous year.

The ongoing pipeline trials continued to progress well, and the company remained on track to deliver the results of the pivotal Birch Phase III trial for Europe in the third quarter of 2018.





At 9:54am: (LON:AGY) Allergy Therapeutics PLC share price was 0p at 28.25p


Story provided by StockMarketWire.com

Forex

Commodities

What the Papers Say

telegraph financial times daily mail daily express independent times
10:01 Sports Direct profits tumble as bet on...
source: The Daily Mail
09:59 Pound hits 10-month low as UK retail sales...
source: The Guardian
09:54 Why do more than half of us think...
source: The Daily Mail
09:52 Buyers misled into using estate agents'...
source: The Daily Mail
09:52 Sports Direct profits tumble as tycoon...
source: The Daily Mail
09:41 Pound hits 10-month low as UK retail sales...
source: The Guardian
09:38 ‘I couldn't pick up my prepaid...
source: The Daily Mail
09:35 The dividend hero shares with yields as...
source: The Daily Mail
09:34 Pound dips below $1.30 for first time in...
source: FT.com
09:24 Chinese yuan hits one-year low as trade...
source: The Guardian
[more ...]